CN Bio expands liver toxicity testing with cross-species organ-on-a-chip models
Cambridge-based biotechnology company CN Bio has enhanced its industry-leading drug-induced liver injury (DILI) assay with new animal microphysiological system models, enabling comparative toxicity studies across human, rat, and dog liver models to improve preclinical drug safety predictions.

